Risk factors for seropositivity to Kaposi sarcoma-associated herpesvirus among children in Uganda. by Wakeham, Katie et al.
Wakeham, K; Webb, EL; Sebina, I; Nalwoga, A; Muhangi, L; Miley,
W; Johnston, WT; Ndibazza, J; Whitby, D; Newton, R; Elliott, AM
(2013) Risk Factors for Seropositivity to Kaposi Sarcoma-Associated
Herpesvirus Among Children in Uganda. Journal of acquired immune
deficiency syndromes (1999), 63 (2). pp. 228-233. ISSN 1525-4135
DOI: 10.1097/QAI.0b013e31828a7056
Downloaded from: http://researchonline.lshtm.ac.uk/1105177/
DOI: 10.1097/QAI.0b013e31828a7056
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
EPIDEMIOLOGY AND PREVENTION
Risk Factors for Seropositivity to Kaposi
Sarcoma–Associated Herpesvirus Among
Children in Uganda
Katie Wakeham, BSc, MBBS,*† Emily L. Webb, PhD,‡ Ismail Sebina, MSc,* Angela Nalwoga, BSc,*
Lawrence Muhangi, MSc,* Wendell Miley, MSc,§ W. Thomas Johnston, PhD,† Juliet Ndibazza, MSc,*
Denise Whitby, PhD,§ Robert Newton, MBBS, DPhil, FFPH,*†k and Alison M. Elliott, MBBS, MD, FRCP*‡
Background: Determinants of Kaposi sarcoma–associated herpesvi-
rus (KSHV) seropositivity among children living in sub-Saharan African
populations where infection is endemic are not well understood. Local
environmental factors, including other infectious agents, may be key.
Methods: Within the context of a well-characterized birth cohort, we
examined associations between various factors and antibodies against
KSHV, measured in stored plasma samples from 1823 mother–child
pairs in Entebbe, Uganda.
Results: Seroprevalence increased with increasing age of the child
(P = 0.0003) and was higher among those with KSHV seropositive
mothers than in those without (12% vs 9%; odds ratio: 1.4, 95%
conﬁdence interval: 1.1 to 2.0). It was also higher among children
with HIV infection (29% vs 10%; odds ratio: 3.1, 95% conﬁdence
interval: 1.2 to 8.3) or malaria parasitemia (30% vs 10%; odds ratio:
4.1, 95% conﬁdence interval: 2.4 to 7.0) than in children without.
These associations were not explained by socioeconomic status.
Conclusions: The ﬁnding that KSHV serostatus is associated with
malaria parasitemia in children is novel. In a country endemic for
KSHV, malaria may be a cofactor for KSHV infection or reactivation
among children.
Key Words: Kaposi sarcoma-associated herpesvirus, Sub-Saharan
Africa, children, HIV, Kaposi sarcoma
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BACKGROUND
Kaposi sarcoma–associated herpesvirus (KSHV) seropre-
valence exhibits marked worldwide geographical variation,1,2
which may represent regional differences in modes of transmis-
sion, or point to the existence of cofactors for infection or
reactivation. Studies from sub-Saharan Africa report high
KSHV prevalence, with primary infection beginning in child-
hood and increasing with age.3,4 There is considerable evidence,
too, that KSHV transmission occurs via saliva5,6 and in Africa
transmission from mothers and siblings, it is likely to be an
important route.4,7 Risk factors governing childhood vulnerabil-
ity to infection with KSHV remain only partly elucidated.
Exposures in childhood including other infectious diseases
may be key. Understanding transmission dynamics is a prereq-
uisite for the development of strategies to prevent spread and
the subsequent diseases associated with this important onco-
genic infection.
This study took place in Uganda, a country with a high
endemic prevalence of KSHV8 and a relatively high incidence
of the Kaposi sarcoma, both among HIV-infected people and
among those without HIV.9,10 We hypothesize that this region
has speciﬁc cofactors driving KSHV transmission. We have
previously reported a high prevalence of antibodies to KSHV
in pregnant women in Uganda, and risk factors for infection
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among these women included certain parasites.8 Few studies
have so far examined parasitic infections as cofactors for sero-
positivity in childhood. This analysis describes the association
between antibodies to KSHV in Ugandan children aged 1–5
years and common local exposures including HIV, malaria,
and helminths in addition to maternal and household factors.
METHODS
Study Population
The investigation was nested within an existing study
in Uganda—the Entebbe Mother and Baby Study—a large
double-blind randomized placebo-controlled trial designed
to determine the impact of helminth infections and their
treatment on vaccine responses and infectious disease out-
comes (International Standard Randomised Controlled Tri-
als No. 32849447). The details of this study have been
reported elsewhere.11 Brieﬂy, consenting women in their
second or third trimester of pregnancy, resident in Entebbe
and Katabi, Uganda were recruited between April 2003 and
November 2005 from the government funded antenatal
clinic. The residential area for the women covers rural,
urban, and ﬁshing communities. At enrolment, sociodemo-
graphic data were collected, and blood samples were
obtained by venepuncture and processed for HIV serology
and CD4 count. Women found to be infected with HIV
were offered single-dose nevirapine to prevent vertical
HIV transmission.
Children were followed from birth and at the time of
this study were between 4 and 5 years old. Children were also
seen for vaccinations and if unwell, for medical treatment. At
routine yearly visits, clinical data, blood for full blood count,
blood slides for malaria and Mansonella perstans, and stool
samples were collected from well children. Any helminth
infections were treated. In addition, at approximately 6 weeks
and 18 months of age, blood samples were obtained from
children of HIV-infected mothers to ascertain the child’s
HIV status. Blood samples from mothers and their children
were processed and plasma stored in the 280°C freezer
archive facility at the Uganda Virus Research Institute (UV-
RI), Entebbe, Uganda.
Diagnosis of Infections
Stool was examined using the Kato-Katz12,13 method for
identiﬁcation of hookworm, Schistosomiasis mansoni, Trichu-
ris trichiura, Ascaris lumbricoides, and Trichostrongylus spe-
cies and by charcoal culture for Strongyloides stercoralis.13
Two slides from a single stool sample were examined for each
individual within 30 minutes for hookworm and the next day
for other ova and parasites. Blood was examined for M. per-
stans by a modiﬁed Knott method.14 Plasmodium falciparum
was diagnosed by examination of thick blood ﬁlms and asymp-
tomatic malaria parasitemia deﬁned as the presence of parasites
without fever. In 6-week-old children, HIV was indicated by
plasma viral load.15 In mothers and children more than 18
months of age, HIV was identiﬁed by serology using a triple
rapid test serial testing algorithm.16
KSHV Serological Testing
The mother’s enrolment plasma sample and the last avail-
able plasma sample for each child were selected for KSHV
serological testing using enzyme-linked immunosorbent assays
(ELISAs) for recombinant proteins K8.1 (a KSHV structural
glycoprotein expressed during lytic infection) and ORF 73 (a
nuclear antigen expressed during latency) as previously
described.8,17,18 The ELISAs were performed at UVRI by the
study lead and a technician, both of whom were blinded to
patient details. The assays were transferred to UVRI from the
Viral Oncology Section, Frederick National Laboratory for
Cancer Research, United States, and have been used in more
than 40 studies worldwide. Analysis of the positive and negative
controls showed comparable performance at Viral Oncology Sec-
tion, Frederick National Laboratory for Cancer Research, and at
UVRI.8 Ten percent of samples were tested in duplicate and
agreement formally tested by calculating a Kappa statistic.19
The Kappa score for agreement for the duplicate samples for
K8.1 was 0.86 and for ORF 73 was 0.92. These scores represent
almost perfect agreement.19
Statistical Analysis
Data were analyzed using Stata11SE (StataCorp LP,
College Station, TX). As individual responses to KSHV
antigens are complex and no gold standard assay exists to
simplify the presentation of results, we combined the K8.1
and ORF 73 results to deﬁne evidence of KSHV infection as
“positive” if either of the 2 assays were positive and “nega-
tive” if both assays were negative. The agreement between
K8.1 and ORF 73 ELISA assays was assessed by calculating
a Kappa statistic.19 A composite variable for household socio-
economic status was derived based on home building materi-
als and number of rooms and items collectively owned at the
mothers home.16 Children were categorized into 3 HIV status
groups: HIV unexposed, HIV exposed (to maternal HIV) but
not infected, and HIV exposed and infected. Because the
prevalence of helminth infections in children was low, a vari-
able for current infection with any helminth was created indi-
cating infection with Trichostrongylus sp, A. lumbricoides,
hookworm, M. perstans, S. mansoni, S. stercoralis, or T.
trichiura. Other risk factors for childhood KSHV seropositiv-
ity considered were (1) childhood variables: gender, age,
asymptomatic malaria parasitemia, and number of previous
symptomatic malaria episodes; (2) maternal factors: KSHV
serostatus, age at birth of child, educational attainment, mar-
ital status, number of babies born alive, number of children
living in the home, personal monthly income, and trial treat-
ment arm; and (3) risk factors for malaria and helminth in-
fections: walking distance to Lake Victoria, type of toilet, use
of mosquito nets, spraying home for mosquitoes, and water
collection source (lake, well, bore hole, stand pipe, tap).
Potential bias in the sample of mother–child pairs was
investigated by comparing the covariate distributions of
mother–child pairs included in this study to the distributions
of those in the cohort who had no samples available for
inclusion. Further to this, mother–child pairs where the child
was lost to follow-up at an early age were compared with
pairs with longer child follow-up.
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The outcome of interest for all analyses was KSHV
serostatus of the child as deﬁned above. The initial analysis
was based on the a priori hypothesis that the age of the child
would be a major determinant of risk of infection. Therefore,
all odds ratios in the initial analysis (model 1) are adjusted for
age of child. A multivariable logistic model (model 2) was
then constructed including all risk factors that were associated
with the outcome at the 5% level in model 1. Statistical
signiﬁcance was assessed using the likelihood ratio test.
Departure from linear trend was considered for all ordered
categorical exposure variables by calculation of a likelihood
ratio test. To assess factors that potentially modify the risk of
a KSHV seropositive mother having a KSHV seropositive
child, interactions between maternal KSHV serostatus and
HIV status or asymptomatic malaria parasitemia in the child
were added to the regression model. No adjustment was made
for multiple comparisons. All P values were 2-sided and we
considered P , 0.05 to be statistically signiﬁcant.
Ethical Approval
Written informed consent was obtained from each woman,
for her own and her child’s participation. Ethical approval for
this study was obtained from the UVRI, Science and Ethics
Committee, Entebbe, Uganda, and the Uganda National Council
for Science and Technology, Kampala, Uganda.
RESULTS
Plasma samples were available for KSHV serological
testing from 1823 (86%) mother–child pairs. Twenty sets of
twins were excluded from these analyses. Maternal age at sam-
pling ranged from 14 to 43 years (median 23 years). The
majority of women (74%) were multigravida and most were
married (85%). The majority of women (85%) reported
a monthly income below the World Bank poverty line of
1.25 USD per day and 25% reported that they could not read.
Antenatal HIV seroprevalence among mothers was 10% with
a median CD4 count for HIV seropositive women of 553 (inter-
quartile range: 368–813) and 4% of women had active syphilis.
Among children, the prevalence of asymptomatic malaria para-
sitemia was 5% and HIV seroprevalence was 1% overall. Hel-
minth infections were rare among children: 3% prevalence of
Trichostrongylus sp and 1% prevalence of A. lumbricoides
infection; hookworm, M. perstans, S. mansoni, S. stercoralis,
and T. trichiura were all detected in fewer than 1% of children.
Mother–child pairs with no samples available for inclu-
sion were more likely to include a HIV seropositive mother
with less education. Mothers of children whose last available
sample was at 1 year were generally younger and more likely
to be HIV seropositive compared with mothers of children
followed up for a longer period.
Among mothers, the prevalence of antibodies to K8.1 was
41% and to ORF 73 was 53%; 32% were seropositive to both
antigens and 61% had antibodies to either K8.1 or ORF 73. The
seroprevalence of KSHV among children was 9% to K8.1, 6%
to ORF 73, 4% to both antigens, and 11% to either ORF 73 or
K8.1. There was moderate concordance between lytic K8.1 and
latent ORF 73 assays in detecting KSHV seropositivity in the
mothers (K = 0.43) and the children (K = 0.46).
Factors signiﬁcantly associated with KSHV seropos-
itivity among children are presented in Table 1. Associations
for age and maternal education were consistent with linear
trends. Of childhood factors, increasing age of the child was
strongly associated with KSHV seropositivity in crude and
adjusted analyses (model 2). Childhood infections with
malaria and HIV were both associated with increased risk
of being KSHV seropositive. Of maternal factors, KSHV
seropositive status and low educational attainment were as-
sociated with KSHV seropositivity in the child; the effect of
maternal KSHV serostatus was reduced by adjusting for other
potential confounders (model 2) and the association with
maternal education was not statistically signiﬁcant. In an anal-
ysis restricted to HIV seropositive mothers, being a HIV sero-
positive child was associated with a 2-fold increase in the
risk of being KSHV seropositive compared with being
a HIV-negative child (odds ratio: 1.9, 95% conﬁdence inter-
val: 0.6 to 5.4). Use of a mosquito net in the home was
marginally associated with a decreased risk of childhood
KSHV seropositivity in model 1, but this association was
not retained after adjusting for other potential confounders
(model 2).
No modiﬁers of the relationship between KSHV
serostatus of the mother and child were detected.
DISCUSSION
In this study of children aged 1–5 years in Uganda, we
have demonstrated for the ﬁrst time an association between
KSHV seropositivity and the presence of asymptomatic malaria
parasitemia. We have also conﬁrmed associations between
KSHV serostatus in Ugandan children and the following cofac-
tors: age of the child, HIV infection in the child, and maternal
KSHV serostatus.
Parasites have been hypothesized as potential cofactors
for KSHV transmission. KSHV is an immune-sensitive
virus,20 and the survival of parasites is dependent on their
ability to interfere with host immune function.21 Ecological
studies from Italy report substantial declines in KSHV sero-
prevalence and Kaposi sarcoma incidence in association with
eradication of mosquitoes.22 It is notable that malaria is
known to affect immune control of another human gamma
herpesvirus, the Epstein–Barr virus. In addition, malaria
interacts with the Epstein–Barr virus thereby increasing the
risk of Burkitt lymphoma, the most common cancer reported
in children in East Africa.23,24 Malaria may impair immune
defence and therefore increase susceptibility to primary
KSHV infection. In addition, malaria infection may cause
KSHV reactivation increasing viral replication and shedding
in saliva. Repeated malaria infections have been shown to
suppress T-cell immunity,25 and this may have a detrimental
effect on the control of KSHV infection. We have previously
reported an association between KSHV seropositivity and
malaria in women in Uganda.8 Longitudinal studies will be
required to examine the nature of this association further.
HIV is an important candidate for inﬂuencing KSHV
transmission rates between KSHV-infected mothers and their
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children. HIV-infected subjects may be more likely to shed
KSHV in saliva and HIV-associated immune deﬁciency may
increase susceptibility to KSHV infection. We found some
evidence that having an HIV-infected mother was a risk factor
for KSHV seropositivity if the child was HIV negative, and
strong evidence that if the child was HIV positive, the odds of
KSHV seropositivity were increased compared with HIV
unexposed uninfected children and with HIV-exposed unin-
fected children. This study conﬁrms the ﬁndings of
others4,18,26 that HIV infection is associated with an increased
seroprevalence of KSHV in children; only 1 study did not
ﬁnd such an association.27 Whether HIV is acting to increase
vulnerability to infection or causing reactivation in children
infected with KSHV in the past will require further longitu-
dinal studies of KSHV infection.
In sub-Saharan Africa, KSHV is endemic and infection
prevalence in children increases with age, suggesting nonsexual
horizontal transmission.28 There is little evidence of vertical
KSHV transmission, or that the virus can be passed through
breast milk.4,29 KSHV is likely to be transmitted through
saliva.5,6 The seroprevalence of KSHV in this study increased
from 4% in children aged 1 year to 15% in 5-year-old children.
In keeping with other studies, KSHV infection status of the
mother was positively associated with infection risk in the
child.4,18 However, nearly a third of KSHV seropositive chil-
dren had a KSHV antibody negative mother. It is possible that
these mothers became infected with KSHV after the antenatal
enrolment sample or that the child was infected from another
source. KSHV transmission within families in sub-Saharan
Africa has been documented with infection risk for the child
TABLE 1. Factors Associated With KSHV Seropositivity in Ugandan Children Aged 1–5 Years
Factor Prevalence*
Age adjusted OR
(95% CI)† P‡
Adjusted OR
(95% CI)§ P‡
Child factors at time of sampling
Age of child (yrs)
1 4% (5/129) 1 1
2 7% (13/182) 1.9 (0.7–5.5) 2.1 (0.7–6.9)
3 10% (70/677) 2.9 (1.1–7.2) 3.6 (1.3–10.3)
4 13% (76/585) 3.7 (1.5–9.3) 5.0 (1.8–14.4)
5 14% (36/250) 4.2 (1.6–10.9) 6.0 (2.0–17.7)
P for trend ,0.0001 0.0003
HIV status if the child (18 missing values)
Not exposed 10% (169/1635) 1 1
Exposed but uninfected 15% (22/143) 1.5 (1.0-2.5) 1.6 (1.0-2.7)
Infected 29% (8/27) 4.3 (1.8-10.2) 3.1 (1.2-8.3)
P for heterogeneity 0.004 0.03
Asymptomatic malaria parasitemia (128 missing values)
No 10% (164/1617) 1 1
Yes 30% (23/78) 3.9 (2.4-6.7) 4.1 (2.4-7.0)
P for heterogeneity ,0.0001 ,0.0001
Maternal and household factors at time of samplingk
Maternal KSHV serostatus
Negative 9% (61/708) 1 1
Positive 12% (139/1115) 1.6 (1.1-2.2) 1.4 (1.0-2.0)
P for heterogeneity ,0.0001 0.04
Maternal education (4 missing values)
None 16% (11/67) 1 1
Primary 12% (110/920) 0.6 (0.3-1.2) 0.5 (0.3-1.1)
Senior 10% (68/670) 0.5 (0.2-1.0) 0.5 (0.2-1.0)
Tertiary 7% (11/162) 0.3 (0.1-0.8) 0.3 (0.1-0.8)
P for trend 0.04 0.08
Use of mosquito net in the home (3 missing values)
No 12% (112/904) 1 1
Yes 10% (97/916) 0.7 (0.6-1.0) 0.8 (0.6-1.1)
P for heterogeneity 0.04 0.3
*KSHV seropositive to either K8.1 or ORF 73.
†All adjusted for age of child (model 1).
‡P value for association of exposure with outcome of KSHV seropositivity.
§All adjusted for age of child, HIV exposure status, asymptomatic malaria parasitemia, maternal KSHV serostatus, maternal education, and use of mosquito net in the home (model 2).
kAntenatal enrolment visit.
OR, odds ratio; CI, conﬁdence interval.
J Acquir Immune Defic Syndr  Volume 63, Number 2, June 1, 2013 Antibodies to KSHV in Ugandan Children
 2013 Lippincott Williams & Wilkins www.jaids.com | 231
showing associations in decreasing order of magnitude with
infection in the mother, father, and next oldest sibling.7 Child-
hood KSHV seropositivity was not associated with maternal
age, in line with other studies in which women had a narrow
age range.30,31
In this study, markers of socioeconomic status, namely
household socioeconomic status, maternal education, maternal
monthly income, and type of toilet, were not associated with
antibodies to KSHV. The absence of an association between
childhood KSHV seropositivity and maternal educational
attainment is in keeping with other studies from sub-Saharan
Africa.26,30 In a recent extensive report of socioeconomic factors
in mother–child pairs in Uganda, the risk of being KSHV sero-
positive was low among mother–child pairs in the high-income
group, although the trend in risk with increasing income was not
linear.30 Other factors including maternal and paternal occupa-
tion, household electricity, and household density were not
found to be associated. Contact with water or collecting water
from ground, stream, river, lake, or wetland sources attracted
particular attention in early reports of risk factors for Kaposi
sarcoma. Ground water was not thought to be a marker of
socioeconomic status, but rather that it may contain a potential
cofactor such as a parasite.30,32,33 In Uganda, previous studies
have investigated type of water supply and antibodies to KSHV.
In children and their mothers, use of surface water for drinking
was associated with an increased risk of KSHV seropositivity in
the crude but not adjusted analysis.30 We found no association
with water source nor did 2 other studies of children and ado-
lescents attending an urban hospital in Uganda.5,34
Our study of a large mother–child population beneﬁted
from the use of robust data, collected through a well-conducted
randomized controlled trial, the initial ﬁndings of which have
been published elsewhere.15 The moderate concordance
between lytic K8.1 and latent ORF 73 assays in detecting
KSHV seropositivity is consistent with previous studies.4,18
However, there were several limitations. The mothers had rel-
atively high CD4 counts and were receiving HIV care that
may have impacted on our ability to assess the role of HIV
alone. The mother’s plasma sample was collected remotely
in time from the child’s sample and the overall number of
HIV-infected children was small. Power to detect potential
associations with childhood helminth infections was small
because of the low prevalence of these infections. Selection
biases may have underestimated the association with HIV
and antibodies to KSHV. Finally, the cross-sectional design
makes it difﬁcult to differentiate between risk factors for
primary infection and reactivation (leading to a boost in
antibody titers). Further longitudinal studies are needed that
collect suitable material to study KSHV viral load and
KSHV-speciﬁc T-cell function.
Cofactors for KSHV transmission are incompletely
understood. Fully elucidating the factors impacting on infec-
tiousness and vulnerability will be the key to reducing KSHV
transmission and thereby the incidence of HIV-associated and
-unassociated Kaposi sarcoma in sub-Saharan Africa. This
study raises new and interesting questions surrounding the
relationship between KSHV and the malaria parasite while
conﬁrming child’s age, HIV infection, and maternal KSHV
status as key cofactors.
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